Back to Results
First PageMeta Content
National Institutes of Health / Biomedical scientist / Health in the United Kingdom / Medical research / Research and development / Marc Tessier-Lavigne / Biologist / Rockefeller University / Drug discovery / Medicine / Health / Pharmaceutical sciences


Microsoft Word - Tessier-Lavigne Testimony.FINAL.docx
Add to Reading List

Document Date: 2014-07-17 08:55:29

Open Document

File Size: 130,21 KB

Share Result on Facebook

City

New York City / /

Company

Genentech / /

Continent

Asia / Europe / /

Country

Taiwan / United States / China / Singapore / South Korea / India / /

Currency

USD / /

Facility

The Rockefeller University / /

IndustryTerm

data-processing tools biologists / biotechnology / massive infrastructure / pharmaceutical breakthroughs / biopharmaceutical sector / pharmaceutical investments / pharmaceutical firms / /

MedicalCondition

psychiatric diseases / Alzheimer’s disease / cancer / HIV / tumors / disease / brain diseases / stroke / heart disease / diabetes / diseases / Infectious diseases / Chronic diseases / such diseases / HIV/AIDS / defeat dementia / poorly treated diseases / metabolic disease / /

MedicalTreatment

antibiotics / drug therapies / /

Organization

Congress / National Institute of Health / Space / and Technology Subcommittee on Research and Technology / federal government / National Science Foundation / Rockefeller University / FDA / U.S. House of Representatives Committee on Science / Technology Subcommittee on Research and Technology / /

Person

Bucshon / Marc Tessier-Lavigne / /

Position

chief scientific officer / Chairman / president / undisputed leader / /

Region

United States U.S. / /

Technology

drug discovery / biotechnology / drug development / human genome / /

URL

http /

SocialTag